Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy
A panel of experts on multiple myeloma give an overview of unique challenges in managing adverse effects associated with CAR T-cell therapy as compared with other cancer therapies.
Now Viewing
EP: 1.Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy
EP: 2.Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach
EP: 3.Patient Profile 1: Managing CRS Following CAR T-Cell Therapy
EP: 4.Underlying Mechanisms and Signs of CRS
EP: 5.Strategies to Manage or Mitigate CRS
EP: 6.Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy
EP: 7.Clinical Practices for Treating ICANS Following CAR T-Cell Therapy
EP: 8.The Importance of Multidisciplinary Collaboration in CRS Management
EP: 9.Supportive Care Strategies for CAR T-Cell Therapy Recipients
EP: 10.Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy
EP: 11.Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM
Video content above is prompted by the following question:
- What are some of the unique challenges in managing adverse events associated with CAR T-cell therapy compared with other cancer therapies?
Recent Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
